NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies

Protea has become a fully owned subsidiary of NasVax

14-Jul-2009 - NasVax Ltd. announced that it has closed the purchase of 100% of the shares of Protea Vaccine Technologies of Kiryat Shmona Israel. As a result, Protea has become a fully owned subsidiary of NasVax. In June 2009, Protea announced that it signed a Research and License Option Agreement with ...

Protea Vaccine Technologies signs an exclusive Research and License Option Agreement with GSK for Pneumococcal vaccine

17-Jun-2009 - Protea Vaccine Technologies Ltd. (Protea), an entity affiliated with NasVax Ltd., announced the execution of a collaboration and option agreement that grants GlaxoSmithKline Biologicals S.A. (GSK) the option to obtain an exclusive license to a set of Protea’s conserved pneumococcal proteins for ...

NasVax and Ramot Announce Licensing Agreement on Novel Immunotherapies for Treatment of Alzheimer's Disease

26-Feb-2009 - NasVax Ltd. and Ramot at Tel Aviv University Ltd. announced that they have signed an agreement on the research, development and commercialization of antibodies and vaccines (the BBS1 Technology) for the treatment and prevention of Alzheimer's disease (AD). Under the terms of the agreement, ...

NasVax Finalizes Share Purchase Agreement with Protea Vaccine Technologies

01-Dec-2008 - NasVax Ltd. announced that it has signed an agreement with Protea Vaccine Technologies Ltd (Protea) to purchase all of the company's shares. Protea is developing an innovative next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal ...

NasVax Commences a Phase I/ IIa Dose-Optimization Clinical Study of VaxiSome-Adjuvanted Influenza Vaccine

05-Nov-2008 - NasVax announced the commencement of a second Phase I/IIa clinical study with VaxiSome-adjuvanted Influenza vaccine, following positive results demonstrated in their final analysis of data from its initial clinical study using VaxiSome when given as a single intramuscular dose. The ...

NasVax Signed a Partnership Agreement with SciGen Ltd. for Developing & Marketing an Improved Hepatitis B Vaccine

19-Dec-2007 - NasVax Ltd. announced that it has entered into a partnership agreement with SciGen Ltd. to develop and market a vaccine administered through the intranasal route for preventing Hepatitis B disease. This development product combines SciGen's Hepatitis B antigen with NasVax's VaxiSomeTM that ...

NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine

17-Aug-2007 - NasVax Ltd., Israeli biotechnology company developing innovative biopharmaceutical products for improving immune responses and administration of vaccines, has announced that it received approval from the Helsinki Committee and the Israel Ministry of Health to perform a Phase 1/2a clinical study ...